Tyr phosphatase-mediated P-ERK inhibition suppresses senescence in EIA + v-raf transformed cells, which, paradoxically, are apoptosis-protected in a MEK-dependent manner

Neoplasia

Volumn 13, Issue 2, 2011, Pages 120-130

  de Vitis, Stefania ^a   Treglia, Antonella Sonia ^a   Ulianich, Luca ^b   Turco, Stefano ^a   Terrazzano, Giuseppe ^c,d   Lombardi, Angela ^a,d   Miele, Claudia ^a,d   Garbi, Corrado ^d   Beguinot, Francesco ^a,d   di Jeso, Bruno ^a  

^a UNIVERSITY OF SALENTO   (Italy)

^b Dipartimento di Biologia e Patologia Cellulare e Molecolare 'L Califano'   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF BASILICATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; E1A PROTEIN; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN TYROSINE PHOSPHATASE; RAF PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL AGING; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SENESCENCE; SIGNAL TRANSDUCTION; THYROID CANCER;

EID: 79951486303     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101152     Document Type: Article

References (46)

1. Emuss V, Garnett M, Mason C, and Marais R (2005). Mutations of C-RAF arerare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65, 9719-9726.
2. Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, et al. (2006). Two transforming C-RAFgerm-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 66, 3401-3408.
3. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, and Rapp UR (1994). Theins and outs of Raf kinases. Trends Biochem Sci 19, 474-480.
4. Kerkhoff E and Rapp UR (1998). Cell cycle targets of Ras/Raf signalling. Oncogene 17, 1457-1462.
5. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, and Cook SJ (2003). Activation of ERK1/2 by delta Raf-1:ER* represses Bimexpression independently of the JNKor PI3K pathways. Oncogene 22, 1281-1293.
6. von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, and Troppmair J (2001). Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21, 2324-2336.
7. Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, and Rapp UR (2000). Raf induces NF-κB by membrane shuttle kinase MEKK1, a signalingpathway critical for transformation. Proc Natl Acad Sci USA 97, 4615-4620.
8. Wang HG, Rapp UR, and Reed JC (1996a). Bcl-2 targets the protein kinase Raf-1to mitochondria. Cell 87, 629-638.
9. Wang HG, Takayama S, Rapp UR, and Reed JC (1996b). Bcl-2 interactingprotein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA 93, 7063-7068.
10. Chen J, Fujii K, Zhang L, Roberts T, and Fu H (2001). Raf-1 promotes cell survivalby antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERKindependent mechanism. Proc Natl Acad Sci USA 98, 7783-7788.
11. O'Neill E, Rushworth L, Baccarini M, and Kolch W (2004). Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267-2270.
12. Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, and Pritchard C (2001). MEK kinase activity is not necessaryfor Raf-1 function. EMBO J 20, 1940-1951.
13. Fabian JR, Daar IO, and Morrison DK (1993). Critical tyrosine residues regulatethe enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 13, 7170-7179.
14. Bosch E, Cherwinski H, Peterson D, and McMahon M (1997). Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Oncogene 15, 1021-1033.
15. Barnard D, Diaz B, Clawson D, and Marshall M (1998). Oncogenes, growthfactors and phorbol esters regulate Raf-1 through common mechanisms. Oncogene 17, 1539-1547.
16. Sheridan C, Brumatti G, and Martin SJ (2008). Oncogenic B-Raf V600E inhibitsapoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem 283, 22128-22135.
17. Serrano M, Lin AW, McCurrach ME, Beach D, and Lowe SW (1997). Oncogenicras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
18. Zhu J, Woods D, McMahon M, and Bishop JM (1998). Senescence of humanfibroblasts induced by oncogenic Raf. Genes Dev 12, 2997-3007.
19. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, and Lowe SW (1998). Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12, 3008-3019.
20. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, et al. (2005). Tumour biology: senescence inpremalignant tumours. Nature 436, 642.
21. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, and Schmitt CA (2005). Oncogene-induced senescenceas an initial barrier in lymphoma development. Nature 436, 660-665.
22. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, and Peeper DS (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
23. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et al. (2005). Distinct sets of genetic alterationsin melanoma. N Engl J Med 353, 2135-2147.
24. Di Jeso B, Park YN, Ulianich L, Treglia AS, Urbanas ML, High S, and Arvan P (2005). Mixed-disulfide folding intermediates between thyroglobulin and endoplasmicreticulum resident oxidoreductases ERp57 and protein disulfide isomerase. Mol Cell Biol 25, 9793-9805.
25. Di Jeso B, Ulianich L, Racioppi L, D'Armiento F, Feliciello A, Pacifico F, Consiglio E, and Formisano S (1995). Serum withdrawal induces apoptotic celldeath in Ki-ras transformed but not in normal differentiated thyroid cells. Biochem Biophys Res Commun 214, 819-824.
26. Mosmann T (1993). Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytoxity assay. J Immunol Methods 65, 55-63.
27. Berlingieri MT, Santoro M, Battaglia C, Grieco M, and Fusco A (1993). Theadenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with otheroncogenes. Oncogene 8, 249-255.
28. Huleihel M, Goldsborough LM, Cleveland J, Gunnell M, Bonner T, and Rapp UR (1986). Characterization of murine A-raf, a new oncogene related to the v-rafoncogene. Mol Cell Biol 6, 2655-2662.
29. Jin S, Zhuo Y, Guo W, and Field J (2005). p21-activated kinase 1 (Pak1)-dependentphosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylationof BAD, and Bcl-2 association. J Biol Chem 280, 24698-24705.
30. den Hertog J, Ostman A, and Böhmer FD (2008). Protein tyrosine phosphatases:regulatory mechanisms. FEBS J 275, 831-847.
31. Evan GI and Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
32. Benhar M, Engelberg D, and Levitzki A (2002). ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3, 420-425.
33. Alavi AS, Acevedo L, Min W, and Cheresh DA (2007). Chemoresistance of endothelialcells induced by basic fibroblast growth factor depends on Raf-1-mediatedinhibition of the proapoptotic kinase, ASK1. Cancer Res 67, 2766-2772.
34. Galmiche A, Fueller J, Santel A, Krohne G, Wittig I, Doye A, Rolando M, Flatau G, Lemichez E, and Rapp UR (2008). Isoform-specific interaction of C-RAF withmitochondria. J Biol Chem 283, 14857-14866.
35. Keyse SM (2008). Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27, 253-261.
36. Saxena M and Mustelin T (2000). Extracellular signals and scores of phosphatases:all roads lead to MAP kinase. Semin Immunol 12, 387-396.
37. Dhillon AS, von Kriegsheim A, Grindlay J, and Kolch W (2007). Phosphataseand feedback regulation of Raf-1 signaling. Cell Cycle 6, 3-7.
38. Tonks NK (2006). Protein tyrosine phosphatases: fromgenes, to function, to disease. Nat Rev Mol Cell Biol 7, 833-846.
39. Ostman A, Hellberg C, and Böhmer FD (2006). Protein-tyrosine phosphatasesand cancer. Nat Rev Cancer 6, 307-320.
40. Sacco F, Tinti M, Palma A, Ferrari E, Nardozza AP, Hooft van Huijsduijnen R, Takahashi T, Castagnoli L, and Cesareni G (2009). Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylationof ERK1/2 kinases. J Biol Chem 284, 22048-22058.
41. O'Shea CC (2005). DNA tumor viruses-the spies who lyse us. Curr Opin Genet Dev 15, 18-26.
42. Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, and Inoue M (2007). Activation of ERK1/2 occurs independentlyof KRAS or BRAF status in endometrial cancer and is associated with favorableprognosis. Cancer Sci 98, 652-658.
43. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, and Becker JC (2008). Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 128, 2003-2012.
44. Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, and Kakudo K (2007). Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 57, 12-20.
45. Jovanovic B, Kröckel D, Linden D, Nilsson B, Egyhazi S, and Hansson J (2008). Lack of cytoplasmic ERK activation is an independent adverse prognostic factor inprimary cutaneous melanoma. J Invest Dermatol 128, 2696-2704.
46. Lee HJ, Kim DI, Kang GH, Kwak C, Ku JH, and Moon KC (2009). Phosphorylationof ERK1/2 and prognosis of clear cell renal cell carcinoma. Urology 73, 394-399.